Oxytocin as a treatment for alcohol use disorder and heavy drinking: A narrative review.

IF 2.4 3区 医学 Q3 PHARMACOLOGY & PHARMACY Experimental and clinical psychopharmacology Pub Date : 2024-09-19 DOI:10.1037/pha0000741
Kriti Rastogi, Elise M Weerts, Jennifer D Ellis
{"title":"Oxytocin as a treatment for alcohol use disorder and heavy drinking: A narrative review.","authors":"Kriti Rastogi, Elise M Weerts, Jennifer D Ellis","doi":"10.1037/pha0000741","DOIUrl":null,"url":null,"abstract":"<p><p>Oxytocin is increasingly being studied for treating symptoms of alcohol use disorders and heavy drinking behavior. The neuropeptide oxytocin facilitates social relationships and modulates the body's stress response by strengthening coping mechanisms and reducing anxiety. Relatedly, oxytocin is also thought to play a role in processes associated with craving and withdrawal from alcohol. This review aims to primarily provide an overview of preclinical and clinical literature on the applications of oxytocin in alcohol use, and additionally discuss a framework for types of trials and the variety of parameters that affect different study designs. A review of the existing literature in this area suggests that while low dosages of oxytocin do not affect drinking behavior and tolerance, higher dosages taken prior to alcohol exposure have varying behavioral and physiological results. Depending on quantity and timing, oxytocin treatments resulted in declines in withdrawal symptoms and alcohol self-administration in preclinical studies and may decrease neural cue reactivity and withdrawal symptoms in clinical studies. Current ongoing trials are expanding on this work to thoroughly explore clinical applications of oxytocin. (PsycInfo Database Record (c) 2024 APA, all rights reserved).</p>","PeriodicalId":12089,"journal":{"name":"Experimental and clinical psychopharmacology","volume":null,"pages":null},"PeriodicalIF":2.4000,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental and clinical psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1037/pha0000741","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Oxytocin is increasingly being studied for treating symptoms of alcohol use disorders and heavy drinking behavior. The neuropeptide oxytocin facilitates social relationships and modulates the body's stress response by strengthening coping mechanisms and reducing anxiety. Relatedly, oxytocin is also thought to play a role in processes associated with craving and withdrawal from alcohol. This review aims to primarily provide an overview of preclinical and clinical literature on the applications of oxytocin in alcohol use, and additionally discuss a framework for types of trials and the variety of parameters that affect different study designs. A review of the existing literature in this area suggests that while low dosages of oxytocin do not affect drinking behavior and tolerance, higher dosages taken prior to alcohol exposure have varying behavioral and physiological results. Depending on quantity and timing, oxytocin treatments resulted in declines in withdrawal symptoms and alcohol self-administration in preclinical studies and may decrease neural cue reactivity and withdrawal symptoms in clinical studies. Current ongoing trials are expanding on this work to thoroughly explore clinical applications of oxytocin. (PsycInfo Database Record (c) 2024 APA, all rights reserved).

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
催产素作为酒精使用障碍和大量饮酒的治疗方法:叙述性综述。
催产素越来越多地被用于治疗酒精使用障碍症状和酗酒行为。神经肽催产素能促进社交关系,并通过加强应对机制和减少焦虑来调节人体的应激反应。与此相关,催产素也被认为在与渴求和戒酒相关的过程中发挥作用。本综述旨在概述催产素在酒精使用中应用的临床前和临床文献,并讨论试验类型框架以及影响不同研究设计的各种参数。对该领域现有文献的回顾表明,虽然低剂量催产素不会影响饮酒行为和耐受性,但在酒精暴露前服用较高剂量的催产素会产生不同的行为和生理结果。在临床前研究中,催产素的剂量和时间会导致戒断症状和酒精自我给药的减少,而在临床研究中,催产素可能会降低神经线索反应性和戒断症状。目前正在进行的试验将在这项工作的基础上进一步深入探索催产素的临床应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
4.20
自引率
8.70%
发文量
164
审稿时长
6-12 weeks
期刊介绍: Experimental and Clinical Psychopharmacology publishes advances in translational and interdisciplinary research on psychopharmacology, broadly defined, and/or substance abuse.
期刊最新文献
Evaluating the human abuse potential of concurrent use of electronic cigarettes and low nicotine cigarettes among adults who smoke. Residual next-day effects of alprazolam on psychomotor performance and simulated driving in healthy normal adults. Efficacy and safety of balovaptan for posttraumatic stress disorder: A randomized, placebo-controlled trial. A behavioral choice analysis of the role of life events during early nonabstinent natural recovery from alcohol use disorder. An experimental investigation into the impact of acute stress on alcohol craving.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1